文献速递痛风与晶体性关节病

焦磷酸钙晶体沉积病的治疗:一项系统综述

Management of calcium pyrophosphate crystal deposition disease: A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2020-12-21

该系统综述检索至2020年5月,纳入22项研究共403例患者,评估焦磷酸钙晶体沉积病(CPPD)的治疗方案。仅3项随机双盲对照试验分别评估甲氨蝶呤、羟氯喹和碳酸镁,除甲氨蝶呤外均显示有效并减轻疼痛。常用药物如非甾体抗炎药、秋水仙碱和糖皮质激素未获随机对照试验评估,高质量证据有限。

要点

  • 仅3项随机双盲对照试验评估CPPD治疗,除甲氨蝶呤外羟氯喹和碳酸镁显示有效并减轻疼痛。
  • 肌肉注射和关节腔内糖皮质激素、ACTH、阿那白滞素和托珠单抗似乎对CPPD有效。
  • 常用药物非甾体抗炎药、秋水仙碱和糖皮质激素未经随机对照试验评估。

核心结论

  • 评估CPPD治疗的研究数量有限,高质量证据相当有限。
  • 常用药物如非甾体抗炎药、秋水仙碱和糖皮质激素未经随机对照试验评估。
  • 亟需高质量证据支持CPPD的特定治疗方式。

研究设计与样本

  • 系统综述,检索在线数据库从建库至2020年5月,纳入评估CPPD特定治疗药物的文章,排除病例报告。
  • 共纳入22项符合条件的研究和403例独特患者。
  • 纳入3项随机双盲对照试验、10项病例系列和9项队列研究。

主要发现

  • 3项随机双盲对照试验分别评估甲氨蝶呤、羟氯喹和碳酸镁,除甲氨蝶呤外均显示有效并减轻疼痛强度。
  • 肌肉注射和关节腔内糖皮质激素、ACTH、阿那白滞素和托珠单抗似乎对CPPD有效。
  • 关节腔内注射糖胺聚糖多硫酸盐、透明质酸和钇,以及激光照射破坏滑膜与症状改善相关。
  • 由于研究异质性显著,无法进行直接比较。

关键数值与推荐

  • 检索词包括CPPD、CPDD、焦磷酸钙、软骨钙化症与治疗、管理、疗法组合。
  • 纳入标准为评估CPPD特定治疗药物的文章,排除病例报告。

临床怎么用

  • 羟氯喹和碳酸镁在随机双盲对照试验中显示有效并减轻疼痛,甲氨蝶呤未显示疗效。
  • 肌肉注射和关节腔内糖皮质激素、ACTH、阿那白滞素和托珠单抗似乎有效。
  • 关节腔内注射糖胺聚糖多硫酸盐、透明质酸和钇,以及激光滑膜破坏与症状改善相关。
  • 非甾体抗炎药、秋水仙碱和糖皮质激素虽常用但缺乏随机对照试验证据。

局限性

  • 评估CPPD治疗的研究数量有限,高质量证据相当有限。
  • 由于研究异质性显著,无法进行直接比较。
  • 常用药物如非甾体抗炎药、秋水仙碱和糖皮质激素未经随机对照试验评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Calcium pyrophosphate crystal deposition disease (CPPD) is a common cause of acute and chronic arthritis, especially in the elderly population. There is a paucity of data regarding the management of CPPD disease, which is currently based on expert opinion and evidence derived from the treatment of gout. We conducted a systematic literature review in order to identify the available treatment options for CPPD, and describe their efficacy and safety. MATERIAL AND METHODS: Online databases were searched from inception to May of 2020 using the search terms: (CPPD [Title/Abstract] OR CPDD [Title/Abstract] OR calcium pyrophosphate [Title/Abstract] OR chondrocalcinosis [Title/Abstract]) AND (treatment [Title/Abstract] OR management [Title/Abstract] OR therapy [Title/Abstract]). Articles evaluating the use of specific treatment agents for CPPD were eligible for inclusion. Case reports were excluded. RESULTS: A total of 22 eligible studies and 403 unique patients were selected. We identified only 3 randomized, double-blind, controlled trials (RCTs) evaluating the use of methotrexate, hydroxychloroquine, and magnesium carbonate in CPPD, and these therapeutic options, with the exception of methotrexate, have shown efficacy and reduction of pain intensity. Further, 10 case series and 9 cohort studies were included. Intramuscular and intra-articular glucocorticoids, ACTH, as well as the biologic agents anakinra and tocilizumab appear to be efficacious in CPPD. Intra-articular injections of glycosaminoglycan polysulphate, hyaluronic acid and yttrium, as well as synovial membrane destruction by laser irradiation were associated with symptomatic improvement. Due to significant study heterogenicity, direct comparison between studies was not possible. CONCLUSION: There are a limited number of studies evaluating the treatment of CPPD. High quality evidence is rather limited, while commonly administered agents such as NSAIDs, colchicine and corticosteroids have not been evaluated by RCTs. The need for high quality evidence supporting specific treatment modalities is urgent for this common yet neglected form of arthritis.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Parperis K, Papachristodoulou E, Kakoullis L, et al. Management of calcium pyrophosphate crystal deposition disease: A systematic review. Semin Arthritis Rheum. 2020. PMID: 33360232. doi:10.1016/j.semarthrit.2020.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。